Brimonidine Drug Delivery System (DDS) Generation 1 in patients with geographic atrophy: Post-hoc analysis of a phase 2 study

被引：0
|
作者：
Kuppermann, Baruch D. [1 ]
Patel, Sunil S. [2 ]
Boyer, David S. [3 ]
Augustin, Albert J. [4 ]
Freeman, William R. [5 ]
Kim, Thomas [6 ]
Kerr, Kevin [6 ]
Lopez, Francisco J. [6 ]
Schneider, Susan [6 ]
机构：
[1] Univ Calif Irvine, UCI Dept Ophthalmol, Gavin Herbert Eye Inst, Irvine, CA USA
[2] West Texas Retina, Abilene, TX USA
[3] Retina Vitreous Associates Med Grp, Los Angeles, CA USA
[4] Stadt Klinikum, Kalsruhe, Germany
[5] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[6] Allergan Plc, Irvine, CA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2017年 / 58卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1924
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
    Kuppermann, Baruch D.
    Patel, Sunil S.
    Boyer, David S.
    Augustin, Albert J.
    Freeman, William R.
    Kerr, Kevin J.
    Guo, Qiang
    Schneider, Susan
    Lopez, Francisco J.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (01): : 144 - 155
  • [2] Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration
    Freeman, William R.
    Bandello, Francesco
    Souied, Eric
    Guymer, Robyn H.
    Garg, Sunir J.
    Chen, Fred K.
    Rich, Ryan
    Holz, Frank G.
    Patel, Sunil S.
    Kim, Kimmie
    Lopez, Francisco J.
    OPHTHALMOLOGY, 2023, 130 (08) : 778 - 779
  • [3] Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration
    Freeman, William R.
    Bandello, Francesco
    Souied, Eric
    Guymer, Robyn H.
    Garg, Sunir J.
    Chen, Fred K.
    Rich, Ryan
    Holz, Frank G.
    Patel, Sunil S.
    Kim, Kimmie
    Lopez, Francisco J.
    BEACON Study Grp
    OPHTHALMOLOGY RETINA, 2023, 7 (07): : 573 - 585
  • [4] Phase 2b Study of Brimonidine DDS: Potential Novel Treatment for Geographic Atrophy
    Freeman, William R.
    Bandello, Francesco
    Souied, Eric H.
    Guymer, Robyn H.
    Garg, Sunir
    Chen, Fred Kuanfu
    Rich, Ryan M.
    Holz, Frank G.
    Li, Yan
    Kerr, Kevin
    Lopez, Francisco J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [5] Brimonidine drug delivery system (Brimo DDS Generation 1) slows the growth of retinal pigment epithelial hypofluorescence following regional blue light irradiation in a nonhuman primate (NHP) model of geographic atrophy (GA)
    Ghosn, Corine
    Almazan, Alexandra
    Decker, Sherri
    Burke, James A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [6] Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema
    Lampen, Shaun I. R.
    Khurana, Rahul N.
    Noronha, Glenn
    Brown, David M.
    Wykoff, Charles C.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2018, 49 (09): : 692 - 697
  • [7] Suprachoroidal Space Alterations after Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients with Diabetic Macular Edema
    Lampen, Shaun Ian Retief
    Khurana, Rahul N.
    Brown, David M.
    Wykoff, Charles Clifton
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [8] Effects of zonisamide on dementia with Lewy bodies (DLB): A post-hoc analysis of phase 2 study for parkinsonism in DLB patients
    Murata, M.
    Nakamura, M.
    Maruyama, H.
    MOVEMENT DISORDERS, 2016, 31 : S437 - S437
  • [9] KarXT treatment improves cognitive performance in cognitively impaired patients with schizophrenia: a post-hoc analysis of the phase 2 EMERGENT-1 study
    Sauder, C.
    Allen, L.
    Baker, E.
    Granger, K.
    Brier, A.
    Kavanagh, S.
    Marcus, R.
    Paul, S.
    Miller, A.
    Brannan, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S580 - S581
  • [10] Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
    Pemmaraju, Naveen
    Garcia, Jacqueline S.
    Potluri, Jalaja
    Harb, Jason G.
    Sun, Yan
    Jung, Paul
    Qin, Qin Q.
    Tantravahi, Srinivas K.
    Verstovsek, Srdan
    Harrison, Claire
    LANCET HAEMATOLOGY, 2022, 9 (06): : E434 - E444
12345